Patents Assigned to Bristol-Myers Squibb
  • Patent number: 10450318
    Abstract: The invention generally relates to compounds of formula I which are antagonists of CXCR4. The invention includes pharmaceutically acceptable salts, compositions, methods of making the compounds of formula I, and methods of using the compounds of formula I for therapeutic indications.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: October 22, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gretchen M. Schroeder, Tram N. Huynh, Heidi L. Perez
  • Patent number: 10451634
    Abstract: Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 22, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Murli Krishna, Alexander T. Kozhich, Martin J. Corbett, Zheng Lin, Steven P. Piccoli
  • Patent number: 10450347
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: October 22, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Claudio Mapelli, Maude A. Poirier, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Patent number: 10450363
    Abstract: Provided herein are proteins comprising a fibronectin based scaffold (FBS) domain, e.g., 10Fn3 molecules, that bind specifically to a target, and wherein the FBS domain is linked at its C-terminus to a region consisting of PmXn, wherein P is proline, X is any amino acid and wherein n is 0 or an integer that is at least 1 and m is an integer that is at least 1, and wherein the PmXn moiety provides an enhanced property to the FBS domain, e.g., enhanced stability, relative to the protein that is not linked to the PmXn moiety.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: October 22, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventor: Dasa Lipovsek
  • Publication number: 20190315870
    Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.
    Type: Application
    Filed: March 22, 2019
    Publication date: October 17, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventors: Michelle Renee KUHNE, Alan J. KORMAN, Haichun HUANG, Yiming YIN, Robert F. GRAZIANO, Natalie A. BEZMAN, Pavel STROP, Richard Y. HUANG, Guodong CHEN, Mohan SRINIVASAN, Peter Sung Keun LEE, Gamze Ozlem CAMDERE
  • Publication number: 20190315865
    Abstract: This disclosure provides a method for treating a subject afflicted with a urothelial carcinoma or cancer derived therefrom, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
    Type: Application
    Filed: October 27, 2017
    Publication date: October 17, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventor: Marina TSCHAIKA
  • Patent number: 10442851
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: October 15, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan Davis, David Fabrizio
  • Patent number: 10435369
    Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 8, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Marcoux, Myra Beaudoin Bertrand, T. G. Murali Dhar, Michael G. Yang, Zili Xiao, Hai-Yun Xiao, Yeheng Zhu, Carolyn A. Weigelt, Douglas G. Batt
  • Patent number: 10435475
    Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: October 8, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Marek Honczarenko, Vaishali Shah, Xiaoni Liu, Wendy L. Trigona, Rong Shi, Suzanne J. Suchard, Karen D. Price, Linda M. Gustavson
  • Patent number: 10435415
    Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: October 8, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Douglas G. Batt, Myra Beaudoin Bertrand, George V. De Lucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
  • Publication number: 20190300592
    Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2R?), wherein IL2 or IL2R? comprises at least one fewer glycosylation site compared to native IL2 or native IL2R?. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 3, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventors: Mary STRUTHERS, Jonathan Harry DAVIS, Michael Louis DOYLE, Priyanka Apurva MADIA
  • Publication number: 20190300608
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Application
    Filed: April 1, 2019
    Publication date: October 3, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia
  • Publication number: 20190300841
    Abstract: The present invention relates to the use of online biomass capacitance monitoring in cultures as a way to control the growth of cells through the use of a temperature control loop. In certain embodiments, a biomass capacitance probe is used to measure the cell density, and a predetermined growth curve is used to adjust the temperature in the culture.
    Type: Application
    Filed: March 28, 2019
    Publication date: October 3, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kathryn L. Aron, Jeffrey Swanberg
  • Patent number: 10428077
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: October 1, 2019
    Assignees: Bristol-Myers Squibb Company, Université de Montréal
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Patent number: 10428151
    Abstract: The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: October 1, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michelle R. Kuhne, Chin Pan, Josephine M. Cardarelli
  • Publication number: 20190290757
    Abstract: This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising nivolumab, a PD-1-blocking antibody, that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.
    Type: Application
    Filed: June 1, 2017
    Publication date: September 26, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventor: Benedetto FARSACI
  • Publication number: 20190292260
    Abstract: This disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
    Type: Application
    Filed: June 2, 2017
    Publication date: September 26, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventor: Marina TSCHAIKA
  • Patent number: 10407422
    Abstract: The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: September 10, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne M. Smallheer, Scott A. Shaw, Oz Scott Halpern, Carol Hui Hu, Ellen K. Kick
  • Patent number: 10406251
    Abstract: Provided herein are novel polypeptides comprising fibronectin type III tenth (10Fn3) domains which specifically bind to Programmed Death Ligand-1 (PD-L1), as well as imaging agents based on the same for diagnostics.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 10, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, David Donnelly, Dasa Lipovsek, Jochem Gokemeijer, Maria N. Jure-Kunkel, David Fabrizio, Martin C. Wright, Douglas Dischino, Samuel J. Bonacorsi, Jr., Ralph Adam Smith, Virginie Lafont, Daniel Cohen
  • Patent number: 10406212
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: September 10, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Alexander T. Kozhich, Martin J. Corbett